Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Calgary Calgary Health Region Ortho Biotech, Inc. |
---|---|
Information provided by: | University of Calgary |
ClinicalTrials.gov Identifier: | NCT00336466 |
Context: Neurocognitive dysfunction complicates coronary artery bypass graft surgery. Neurocognitive dysfunction is a measurable problem with thinking. Erythropoietin may be a neuroprotectant.
Objective: To investigate the feasibility and safety of three doses of human recombinant erythropoietin to reduce neurocognitive dysfunction in coronary artery bypass graft patients.
Condition | Intervention | Phase |
---|---|---|
Cardiac Surgery Brain Injury |
Drug: Human recombinant erythropoietin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial. |
Estimated Enrollment: | 32 |
Study Start Date: | September 2004 |
Estimated Study Completion Date: | May 2005 |
Coronary artery bypass surgery (CABG) is performed each year on over 500,000 patients in the US and almost 30,000 patients in Canada to treat coronary artery disease. However, it is complicated by a significant postoperative risk of neurologic sequelae, including stroke and neurocognitive dysfunction (NCD). Clinically overt stroke, which may be seen in 1-4% of patients, is far less common than NCD, which is reported in approximately 50-75% of patients at discharge, 20-50% at 6 weeks and up to 40% at five years.Human recombinant erythropoietin (rh-Epo) is not only approved in this population for prophylactic use to reduce blood transfusions, but has become an agent of intense interest for neuroprotection as a result of in vitro data, animal experiments, and now, two promising preliminary trials in human patients. There are not, however, any pilot data by which to estimate an appropriate dose or treatment effect of rh-Epo on NCD specifically. It is imperative both to refine estimates of control group incidence rates, treatment effect and test variability in CABG, as well to demonstrate the feasibility and safety of a study protocol, prior to embarking on a larger randomized controlled trial powered with an adequate sample size to investigate the efficacy of rh-Epo in the reduction of peri-operative NCD. We propose a six month prospective study in CABG patients to investigate the feasibility and safety of three prophylactic doses of human recombinant erythropoietin (rh-Epo) in a randomized, placebo controlled study. The four study arms are: placebo, 375 U/kg, 750 U/kg, or 1500 U/kg of human recombinant erythropoietin intravenously divided in three doses, the day before, the day of and the day after surgery. The primary outcomes of this pilot will be study feasibility and patient safety as measured by ICU and Hospital length of stay, 28 day all cause mortality, and incidence of morbidity including pure red cell aplasia (PRCA), stroke, myocardial infarction, re-operation, deep vein thrombosis, and pulmonary thromboembolism. The secondary outcome will be the incidence of neurocognitive dysfunction among the four study arms and between placebo and rh-Epo at any dose. As well, little is known about the pharmacology of rh-Epo in crossing the blood-brain barrier. In those patients receiving a spinal anesthetic in addition to a general anesthetic as part of their normal care, CSF will be analyzed for rh-Epo concentration, and then compared to drug dose and serum level.
Ages Eligible for Study: | 45 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Alberta | |
Foothills Hospital | |
Calgary, Alberta, Canada, T2N 2T9 |
Principal Investigator: | David Zygun, MD | University of Calgary and Calgary Health Region |
Study ID Numbers: | 17747 |
Study First Received: | June 12, 2006 |
Last Updated: | November 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00336466 |
Health Authority: | Canada: Health Canada |
Cardiac bypass surgery |
Epoetin Alfa Craniocerebral Trauma Wounds and Injuries Disorders of Environmental Origin |
Central Nervous System Diseases Trauma, Nervous System Brain Diseases Brain Injuries |
Hematinics Therapeutic Uses Hematologic Agents Nervous System Diseases Pharmacologic Actions |